Evidence map›Paper›PMID 32232664›Full record

ReviewAdvances in therapy2020

Barriers to the Wider Use of Pre-exposure Prophylaxis in the United States: A Narrative Review.

Kenneth H Mayer, Allison Agwu, David Malebranche

Registry-linked trialOpen access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advances in therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05977881 (Impact of a Novel HIV Peer Navigation and Overdose Prevention Intervention on Engagement in the HIV Prevention and Treatment Cascade), which is not on this map. Cited by 269 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
269citing papers in PubMed, 11 pooled it
5.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05977881 nacompletednot on this mapstarted 2023, after this paper: background citation

Impact of a Novel HIV Peer Navigation and Overdose Prevention Intervention on Engagement in the HIV Prevention and Treatment Cascade

TypeinterventionalSponsorJohns Hopkins Bloomberg School of Public HealthRan2023 to 2026Enrolled493ConditionsHIV InfectionsArmsCHECKIT!
3 · Its place in the literature

Who cites it

269 citing papers in PubMed, 11 syntheses or guidelines pooled it, 404 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pre-exposure Prophylaxis Adherence Among Men Who Have Sex With Men: A Systematic Review and Meta-analysis.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2024
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

209 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Kenneth H MayerThe Fenway Institute and Harvard Medical School, Boston, MA, USA. khmayer@gmail.com.
Allison AgwuJohns Hopkins University School of Medicine, Baltimore, MD, USA.
David MalebrancheMorehouse School of Medicine, Atlanta, GA, USA.
Fenway Health · USJohns Hopkins Medicine · USMorehouse School of Medicine · US

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI RAJESH T GANDHI · 2004 to 2026
$94.4M
NIAID NIH HHS P30 AI060354
6 · The paper itself

Abstract

Antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV transmission was first approved by the US Food and Drug Administration in 2012. Despite correlations of decreases in new HIV infections being greatest where PrEP has been deployed, the uptake of PrEP is lagging, particularly among populations with disproportionate HIV burden. This narrative review seeks to identify individual and systemic barriers to PrEP usage in the USA. A comprehensive search of recent literature uncovered a complex array of structural, social, clinical, and behavioral barriers, including knowledge/awareness of PrEP, perception of HIV risk, stigma from healthcare providers or family/partners/friends, distrust of healthcare providers/systems, access to PrEP, costs of PrEP, and concerns around PrEP side effects/medication interactions. Importantly, these barriers may have different effects on specific populations at risk. The full potential of PrEP for HIV prevention will not be realized until these issues are addressed. Strategies to achieve this goal should include educational interventions, innovative approaches to delivery of HIV care, financial support, and destigmatization of PrEP and PrEP users. Until then, PrEP uptake will continue to be suboptimal, particularly among those who need it most.

Indexed as

Attitude of Health PersonnelAdultAnti-HIV AgentsDrug UtilizationFemaleHealth PersonnelHIV InfectionsHumansMaleMiddle AgedPre-Exposure ProphylaxisUnited StatesAnti-HIV AgentsAccessBarriersDistrustEmtricitabineImplementationPre-exposure prophylaxisPreventionStigmaTenofovir alafenamideTenofovir disoproxil fumarate

Identifiers

PMID32232664
PMCPMC7467490
OpenAlexW3013272485

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.